Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 22, 2024 16:05 ET
|
Vera Therapeutics
BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera’s Board of Directors granted...
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
November 18, 2024 08:00 ET
|
Vera Therapeutics
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 11, 2024 16:05 ET
|
Vera Therapeutics
Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting...
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
November 11, 2024 08:00 ET
|
Vera Therapeutics
Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands...
Vera Therapeutics to Participate at Upcoming Investor Conferences
November 08, 2024 16:05 ET
|
Vera Therapeutics
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics to Participate at Upcoming Investor Conferences
November 08, 2024 08:00 ET
|
Vera Therapeutics
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 07, 2024 08:00 ET
|
Vera Therapeutics
Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN)...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
October 29, 2024 20:21 ET
|
Vera Therapeutics
BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
October 28, 2024 17:37 ET
|
Vera Therapeutics
BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
October 26, 2024 19:30 ET
|
Vera Therapeutics
Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;Long-term results from the...